La Jolla Pharmaceutical Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From La Jolla Pharmaceutical Company
Viewers spend more time on print ads that have more lengthy important safety information or a brief summary but impact on understanding is unclear, OPDP study finds. Another study finds exaggerated images of drug benefits in TV ads unsurprisingly can mislead consumers.
Agency cites video promoting Biohaven’s Nurtec ODT, which first aired on ABC’s TV show The View, for misleading comparative claims, inadequate display of risk information, and failure to submit promo for review.
Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
- Other Names / Subsidiaries
- La Jolla Pharma, LLC
- Tetraphase Pharmaceuticals, Inc.